During the past grant period Roswell Park Cancer Institute (RPCI) has undergone continued growthin scientific, clinical trials and cancer education programs. This growth has been guided by internal andexternal advisory groups and led by the CCSG senior leadership. The primary forums in which planning andevaluation are carried out include the Executive Council, CCSG Program Steering Committee, ProgramExternal Advisory Boards and Institute CCSG External Advisory Board meetings. Disease-specific researchgroup meetings occur monthly and bring together preclinical and clinical investigators committed to the studyof specific diseases. In addition yearly CCSG retreats are held to bring together CCSG members to discussand develop the CCSG Programs and explore needs for new scientific core resources, latest was held inNovember 2006.The succession of Dr. Donald Trump to the position of CCSG PI and President/CEO was the result ofcareful planning and evaluation by Dr. Hohn, Dr. Trump's predecessor, the RPCI Board of Directors (BOD)and external advisors to the RPCI BOD.With this transition, Dr. Trump and the CCSG senior leadership are poised to develop a robust longtermstrategic plan for the CCSG and the Institute as a whole - based on and growing from theCCSG/lnstitute strategic plan developed in 2004 by senior leadership.Funds requested in this application will be used to affect some of the costs of the annual CCSG EABmeetings and RPCI member retreats, while other planning and evaluation activities will be supported byInstitute resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-32
Application #
7714408
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-07-28
Project End
2013-04-30
Budget Start
2008-07-28
Budget End
2009-04-30
Support Year
32
Fiscal Year
2008
Total Cost
$25,636
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Eng, Diana G; Kaverina, Natalya V; Schneider, Remington R S et al. (2018) Detection of renin lineage cell transdifferentiation to podocytes in the kidney glomerulus with dual lineage tracing. Kidney Int 93:1240-1246
Ling, Xiang; Wu, Wenjie; Fan, Chuandong et al. (2018) An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res 37:240
Chung, Sejin; Vail, Paris J; Witkiewicz, Agnieszka K et al. (2018) Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clin Cancer Res :
Mohammadpour, Hemn; O'Neil, Rachel; Qiu, Jingxin et al. (2018) Blockade of Host ?2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs. J Immunol 200:2479-2488
Hsu, Alice H; Lum, Michelle A; Shim, Kang-Sup et al. (2018) Crosstalk between PKC? and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium. Cell Rep 24:655-669
Sandlesh, Poorva; Juang, Thierry; Safina, Alfiya et al. (2018) Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene. PLoS One 13:e0199785
Zhang, Dingxiao; Zhao, Shuhong; Li, Xinyun et al. (2018) Prostate Luminal Progenitor Cells in Development and Cancer. Trends Cancer 4:769-783
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Damayanti, Nur P; Budka, Justin A; Khella, Heba W Z et al. (2018) Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clin Cancer Res 24:5977-5989
Mayor, Paul; Starbuck, Kristen; Zsiros, Emese (2018) Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. Gynecol Oncol 150:361-369

Showing the most recent 10 out of 1555 publications